Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04298034

Preeclampsia Postpartum Antihypertensive Treatment

The goal of this study is to compare whether antihypertensive treatment in the postpartum period decreases postpartum hypertension and its associated maternal morbidity, including risk of readmission and healthcare utilization in comparison with no treatment. Women with preeclampsia diagnosed during the antepartum, intrapartum or postpartum period will be randomized to either initiate antihypertensive treatment or standard of care. We hypothesize that postpartum antihypertensive treatment of patients with preeclampsia will decrease risk of hospital readmission, healthcare utilization and the number of severe range blood pressures at postpartum follow-up visits.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Medical College of Wisconsin-Froedtert Hospital

Milwaukee, Wisconsin, 53226, United States

About this study

This will be a randomized, controlled trial of 300 women with a diagnosis of preeclampsia at any point in their current pregnancy or immediately postpartum. Immediately postpartum is defined as preeclampsia diagnosed after delivery but prior to discharge from the hospital. The diagnosis of preeclampsia will be made using standardized definitions by the American College of Obstetrics and Gynecology. Preeclampsia is diagnosed with new-onset hypertension of blood pressure of greater than or equal to 140 systolic blood pressure or greater than or equal to 90 diastolic blood pressure recorded twice at least four hours apart AND proteinuria, defined as 300mg of protein in a 24hour urine collection or a protein/creatinine ratio of 0.3. If the above blood pressure criteria are met and there is not proteinuria, preeclampsia can still be diagnosed if there is thrombocytopenia with platelet count of less than 100,000, renal insufficiency with creatinine of greater than 1.1 or twice the patient's individual baseline, impaired liver function with AST or ALT twice normal or epigastric/right upper quadrant pain, pulmonary edema, new-onset headache unresponsive to medication, or visual disturbance. All of these findings should not be explained by an alternative diagnosis.

Women will be consented and randomized at the time of their diagnosis, within 96 hours of their delivery. The patients randomized to the treatment group will have an antihypertensive medication prescribed to them. The specific medication will be either labetalol, nifedipine or hydralazine based on allergies and clinically appropriateness of the medication. The patient will be instructed on the dosing, timing, and possible adverse effects. All subject's blood pressures will be monitored per standard postpartum protocols. As per standard practice, all patients with preeclampsia will be asked to return at 7-10 days for a blood pressure check and then again at 6 weeks for a complete postpartum assessment.

Consent of patients, review of blood pressures, data collection and storage, and statistical analysis will be performed at the Medical College of Wisconsin (MCW) through the Maternal Fetal medicine department. Women will be allowed to continue routine antenatal, intrapartum and postpartum care with their primary obstetrician. The research team will follow enrolled patients through the 6-week postpartum follow up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >= 18 years old
  • Immediately postpartum (delivered in previous 96 hours)
  • Diagnosed with preeclampsia during pregnancy, labor or immediately postpartum
  • >30% of blood pressures in the postpartum period were elevated (systolic 140 or higher OR diastolic 90 or higher)

Exclusion criteria

  • Chronic hypertension with superimposed preeclampsia
  • Diagnosis of preeclampsia after discharge from delivery hospitalization
  • Persistent severe range blood pressures after delivery requiring initiation of antihypertensive regimen by the care team
  • >50% of blood pressures in the postpartum period were normal (systolic less than 140 AND diastolic less than 90)

Treatment and study plan

Labetalol, Nifedipine

Drug

Antihypertensive treatment that is safe and well studied in peripartum women.

Other names: Procardia, Trandate, Normodyne

Primary outcomes

  1. Hospital Readmission

    Time frame: Within 6 weeks from delivery

Secondary outcomes

  1. Rate of Healthcare Utilization

    Time frame: Within 6 weeks from delivery

    hospital readmissions, increased number of postpartum visits or phone calls, emergency room or urgent care visits, consultation with primary care (internal medicine, family medicine), cardiology, or maternal-fetal-medicine specialists

  2. percentage of severe range blood pressures at the 7-10 days postpartum visit

    Time frame: 7-10 days postpartum

  3. percentage of severe range blood pressures at the 6 week postpartum visit

    Time frame: Approximately 6 weeks postpartum

  4. compare mean systolic and mean diastolic blood pressure values at 7-10 days postpartum and at 6weeks postpartum

    Time frame: 6 weeks pospartum

Sponsors and collaborators

Lead sponsor

Medical College of Wisconsin

Other

Registry information

Official study title

Randomized Controlled Trial for Postpartum Antihypertensive Treatment of Women With Preeclampsia

Acronym: P-PAT

Important dates

Study start
2020
Primary completion
2025
Study completion
2026
First posted
Mar 6, 2020
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.